By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today provided guidance for its 2012 fiscal year, projecting net income to improve between 20 and 30 percent above projected fiscal 2011 income on the strength of its illumigene franchise.

For the year ending Sept. 30, 2012, the company expects EPS to fall between $.85 and $.89 on net sales of between $183 million and $192 million. The guidance excludes reorganization costs in 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.